SCHEMBL6843947

SCHEMBL6843947

O=C(O)CCCc1ccccc1-c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 6/20 0.63
PTGER3 P43115 6/20 0.63
PTGER1 P34995 5/20 0.63
PTGER2 P43116 5/20 0.63
HDAC3 O15379 1/20 0.55
MAPK1 P28482 1/20 0.55
ADRA1A P35348 1/20 0.55
HDAC4 P56524 1/20 0.55
SLC6A3 Q01959 1/20 0.55
HDAC1 Q13547 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
HDAC7 Q8WUI4 1/20 0.55
HDAC2 Q92769 1/20 0.55
HDAC10 Q969S8 1/20 0.55
HDAC11 Q96DB2 1/20 0.55
HDAC8 Q9BY41 1/20 0.55
HDAC6 Q9UBN7 1/20 0.55
HDAC9 Q9UKV0 1/20 0.55
HDAC5 Q9UQL6 1/20 0.55
FFAR4 Q5NUL3 3/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28313950 0.95 PTGER1 (0.61) PTGER4PTGER3PTGER1PTGER2HDAC3
SCHEMBL28959383 0.93 PTGER1 (0.59) PTGER4PTGER3PTGER1PTGER2HDAC3
SCHEMBL28417410 0.93 PTGER1 (0.59) PTGER4PTGER3PTGER1PTGER2HDAC3
SCHEMBL11069817 0.93 PTGER1 (0.59) PTGER4PTGER3PTGER1PTGER2HDAC3
SCHEMBL16178552 0.93 PTGER1 (0.59) PTGER4PTGER3PTGER1PTGER2HDAC3
Bromide SCHEMBL27464773 0.91 PTGER1 (0.58) PTGER4PTGER3PTGER1PTGER2HDAC3
SCHEMBL1261128 0.89 PTGER4 (0.77) PTGER4PTGER3PTGER1PTGER2FFAR4
SCHEMBL31212507 0.89 PTGER4 (0.77) PTGER4PTGER3PTGER1PTGER2FFAR4
SCHEMBL6053663 0.87 PTGER4 (0.81) PTGER4PTGER3PTGER1PTGER2FFAR4
SCHEMBL8479912 0.87 PTGER4 (0.70) PTGER4PTGER3PTGER1PTGER2FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1354740-A Pharmaceutical compounds NICOX SA (FR) 2002-06-19 CN claimed
CN-119857095-A Choroidal neovascularization inhibitor or drusen inhibitor and its evaluation or screening method 林科杰诺米克斯股份有限公司 2025-04-22 CN disclosed
CN-114716544-B Complement component C5 antibodies 阿勒根公司 2024-10-01 CN disclosed
CN-118251208-A Degradable intrauterine system for prolonged release of active ingredient in uterine cavity 沃梅德公司 2024-06-25 CN disclosed
CN-111630154-B Enhancing fibroblast regeneration activity 菲格内有限责任公司 2024-06-07 CN disclosed
CN-115996686-B Medical device comprising expandable muscle polymer 巴德外周血管股份有限公司 2024-03-22 CN disclosed
CN-112041294-B Co-crystals of panthenol and compositions comprising said co-crystals 晶体工程智能研究中心 2024-02-20 CN disclosed
CN-110582286-B Ocular application of matrix-bound vesicles (MBVs) 联邦高等教育系统匹兹堡大学 2024-01-30 CN disclosed
CN-115996686-A Medical device comprising expandable muscle polymer 巴德外周血管股份有限公司 2023-04-21 CN disclosed
CN-114716544-A Complement component C5 antibody 阿勒根公司 2022-07-08 CN disclosed
US-20040176393-A1 Statin-MMP inhibitor combinations NEWTON ROGER SCHOFIELD (US) 2004-09-09 US disclosed
EP-1189882-A1 BIPHENYL BUTYRIC ACID DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS Co. Ltd. (KR) 2002-03-27 EP disclosed
WO-2001083445-A1 BIPHENYL BUTYRIC ACID DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2001-11-08 WO disclosed
WO-1995029892-A1 HYDROXAMIC ACID AND AMINO ACID DERIVATIVES AND THEIR USE AS ANTI-ARTHRITIC AGENTS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1995-11-09 WO disclosed
EP-0470832-B1 Biphenyl 5,5'-bis-alkanoic acid derivatives, their production and use thereof ASAHI CHEMICAL IND (JP) 1994-12-14 EP disclosed
US-5326495-A Tetrasubstituted methanes having liquid-crystalline properties CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) 1994-07-05 US disclosed
US-5155259-A High stability; prevention and therapy of diabetic complications TOYO JOZO KABUSHIKI KAISHA (JP) 1992-10-13 US disclosed
US-5136090-A Antidiabetic agents TOYO JOZO KABUSHIKI KAISHA (JP) 1992-08-04 US disclosed
EP-0470832-A2 Biphenyl 5,5'-bis-alkanoic acid derivatives, their production and use thereof ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1992-02-12 EP disclosed
US-3966801-A ANTIINFLAMMATORY AGENTS WILLIAM H. RORER, INC. (US) 1976-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176393-A1 Statin-MMP inhibitor combinations MMP9, TIMP3, MMP3 PTGER4 340/4885PTGER3 203/4885PTGER1 144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.